nach oben

Neurological Sciences

Erschienen in:

07.01.2022 | Review Article

Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis

verfasst von: Christian Wilson R. Turalde, Kevin Michael C. Moalong, Adrian I. Espiritu, Mario B. Prado Jr.

Erschienen in: Neurological Sciences | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease. There is still no established cost-effective treatment that can improve functional status and survival of ALS patients. Perampanel, by inhibiting neuronal calcium ion influx and preventing dyslocalization of nuclear proteins, has the potential to ameliorate ALS neurodegeneration.

Objectives

This study aims to determine the efficacy and safety of perampanel among ALS patients in terms of improvement in functional status using a review of relevant studies.

Methods

MedLine, Cochrane Central Register for Controlled Trials, Scopus, Embase, Literatura Latino-Americana e do Caribe em Ciências da Saúde, ClinicalTrials.gov website, and HERDIN databases were searched from inception to August 2021 for relevant studies.

Results

The search yielded 132 articles; 3 studies were included in the analysis. Pooled evidence shows that perampanel compared to placebo significantly improves cortical motor hyperexcitability but not the ALS functional rating scale-revised score. Perampanel is associated with adverse events such as aggression, somnolence, anger, and dysarthria.

Conclusion

There is no sufficient evidence to support the role of perampanel in improving functional status of ALS patients. Although it can ameliorate motor cortical hyperexcitability, its clinical benefit has not yet been elucidated. Perampanel is not well tolerated among ALS patients as it is associated with adverse events such as aggression, somnolence, anger, and dysarthria. Further studies investigating the role of perampanel early in the ALS disease course, excluding ALS patients with frontotemporal lobe degeneration features and C9ORF72 repeat expansion, and using gradual drug titration schedule are needed to evaluate the potential benefit of perampanel in ALS.

Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:17071. https://doi.org/10.1038/nrdp.2017.71CrossRefPubMed

van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084–2098. https://doi.org/10.1016/S0140-6736(17)31287-4CrossRefPubMed

Chiò A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130. https://doi.org/10.1159/000351153CrossRefPubMed

Foster LA, Salajegheh MK (2019) Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med 132:32–37. https://doi.org/10.1016/j.amjmed.2018.07.012CrossRefPubMed

Blokhuis AM, Groen EJN, Koppers M et al (2013) Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 125:777–794. https://doi.org/10.1007/s00401-013-1125-6CrossRefPubMedPubMedCentral

Gordon P (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 04:295–310. https://doi.org/10.14336/AD.2013.0400295CrossRef

Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463–477. https://doi.org/10.1038/nri3705CrossRefPubMed

Kiernan MC, Vucic S, Talbot K et al (2021) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 17:104–118. https://doi.org/10.1038/s41582-020-00434-zCrossRefPubMed

Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001447.pub3CrossRefPubMedPubMedCentral

10.

Abe K, Aoki M, Tsuji S et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505–512. https://doi.org/10.1016/S1474-4422(17)30115-1CrossRef

11.

Paganoni S, Macklin EA, Hendrix S et al (2020) Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383:919–930. https://doi.org/10.1056/NEJMoa1916945CrossRefPubMedPubMedCentral

12.

Paganoni S, Hendrix S, Dickson SP et al (2021) Long-term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrate-taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. Muscle Nerve 63:31–39. https://doi.org/10.1002/mus.27091CrossRefPubMed

13.

Tavakoli M, Malek M (2001) The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 191:95–102. https://doi.org/10.1016/S0022-510X(01)00618-9CrossRefPubMed

14.

Messori A, Trippoli S, Becagli P, Zaccara G (1999) Cost effectiveness of Riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics 16:153–163. https://doi.org/10.2165/00019053-199916020-00004CrossRefPubMed

15.

Yeo CJJ, Simmons Z (2018) Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotroph Lateral Scler Front Degener 19:167–172. https://doi.org/10.1080/21678421.2018.1425455CrossRef

16.

Sills GJ, Rogawski MA (2020) Mechanisms of action of currently used antiseizure drugs. Neuropharmacology 168:107966. https://doi.org/10.1016/j.neuropharm.2020.107966CrossRefPubMed

17.

Akamatsu M, Yamashita T, Hirose N et al (2016) The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6:28649. https://doi.org/10.1038/srep28649CrossRefPubMedPubMedCentral

18.

Oskarsson B, Mauricio EA, Shah JS et al (2021) Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64:215–219. https://doi.org/10.1002/mus.27328CrossRefPubMed

19.

Hotait M, Ismail HH, Saab GE, Salameh JS (2021) An open label pilot study of the safety and tolerability of Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64(4):504–508. https://doi.org/10.1002/mus.27385

20.

Aizawa H, Kato H, Oba K et al (2021) Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol. https://doi.org/10.1007/s00415-021-10670-yCrossRefPubMedPubMedCentral

21.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

22.

Ludolph A, Drory V, Hardiman O et al (2015) A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Front Degener 16:291–292. https://doi.org/10.3109/21678421.2015.1049183CrossRef

23.

Nodera H, Izumi Y, Kaji R (2007) New diagnostic criteria of ALS (Awaji criteria). Brain Nerve 59:1023–1029. https://doi.org/10.11477/mf.1416100142CrossRefPubMed

24.

Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169:13–21. https://doi.org/10.1016/S0022-510X(99)00210-5CrossRefPubMed

25.

Mackenzie IRA, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434. https://doi.org/10.1002/ana.21147CrossRefPubMed

26.

Guo C, Ma Y-Y (2021) Calcium Permeable-AMPA receptors and excitotoxicity in neurological disorders. Front Neural Circuits 15:711564. https://doi.org/10.3389/fncir.2021.711564

27.

Barmada SJ, Skibinski G, Korb E et al (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30:639–649. https://doi.org/10.1523/JNEUROSCI.4988-09.2010

28.

Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19:R46–R64. https://doi.org/10.1093/hmg/ddq137CrossRefPubMedPubMedCentral

29.

Osawa T, Mizuno Y, Fujita Y et al (2011) Optineurin in neurodegenerative diseases. Neuropathology 31:569–574. https://doi.org/10.1111/j.1440-1789.2011.01199.xCrossRefPubMed

30.

Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. https://doi.org/10.1016/j.neuron.2011.09.010CrossRefPubMedPubMedCentral

31.

Deng H-X, Chen W, Hong S-T et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–215. https://doi.org/10.1038/nature10353CrossRefPubMedPubMedCentral

32.

Elden AC, Kim H-J, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069–1075. https://doi.org/10.1038/nature09320CrossRefPubMedPubMedCentral

33.

Jaiswal MK (2017) Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediated excitotoxicity induced disrupted mitochondrial Ca2+ signaling in amyotrophic lateral sclerosis. Front Cell Neurosci 10:295. https://doi.org/10.3389/fncel.2016.00295

34.

Keon M, Musrie B, Dinger M et al (2021) Destination amyotrophic lateral sclerosis. Front Neurol 12:596006. https://doi.org/10.3389/fneur.2021.596006

35.

Youn SE, Kim SH, Ko A et al (2018) Adverse events during perampanel adjunctive therapy in intractable epilepsy. J Clin Neurol 14:296. https://doi.org/10.3988/jcn.2018.14.3.296CrossRefPubMedPubMedCentral

36.

Rugg-Gunn F (2014) Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 55:13–15. https://doi.org/10.1111/epi.12504CrossRefPubMed

37.

Abramzon YA, Fratta P, Traynor BJ, Chia R (2020) The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 14:42. https://doi.org/10.3389/fnins.2020.00042

38.

Ling S-C, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:416–438. https://doi.org/10.1016/j.neuron.2013.07.033CrossRefPubMedPubMedCentral

39.

Montuschi A, Iazzolino B, Calvo A et al (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86:168–173. https://doi.org/10.1136/jnnp-2013-307223CrossRefPubMed

40.

Gotovac K, NikolacPerković M, Pivac N, Borovečki F (2016) Biomarkers of aggression in dementia. Prog Neuro-Psychopharmacology Biol Psychiatry 69:125–130. https://doi.org/10.1016/j.pnpbp.2016.03.002CrossRef

41.

Grochmal-Bach B, Bidzan L, Pachalska M et al (2009) Aggressive and impulsive behaviors in Frontotemporal dementia and Alzheimer’s disease. Med Sci Monit 15:CR248-54PubMed

42.

Byrne S, Elamin M, Bede P et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11:232–240. https://doi.org/10.1016/S1474-4422(12)70014-5CrossRefPubMedPubMedCentral

43.

Bersano E, Sarnelli MF, Solara V et al (2020) Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Front Degener 21:373–379. https://doi.org/10.1080/21678421.2020.1771732CrossRef

Titel: Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis
verfasst von: Christian Wilson R. Turalde
Kevin Michael C. Moalong
Adrian I. Espiritu
Mario B. Prado Jr.
Publikationsdatum: 07.01.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 2/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05867-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Cognitive trajectories in multiple sclerosis: a long-term follow-up study

Autoimmune encephalitis: the first observational study from Iran

Pure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine

Multifocal motor neuropathy occurring after acute motor axonal neuropathy: two stages of the same disease?

Structural and functional connections between the autonomic nervous system, hypothalamic–pituitary–adrenal axis, and the immune system: a context and time dependent stress response network